Tenaya's TN-201 Gene Therapy Shows Consistent Cardiac Improvement, Symptom Reduction in Interim Trial Data
TNYA sits 91% above its 52-week low of $0.44.
Summary
Tenaya Therapeutics announced positive interim data from its Mypeak™-1 clinical trial for TN-201 gene therapy in patients with Mybpc3-associated HCM. All evaluable patients showed consistent signs of cardiac remodeling and reductions in symptoms. Benefits were sustained up to two years in Cohort 1, with earlier improvements seen in Cohort 2. The TN-201 therapy was well tolerated with no new safety events reported, which is critical for a gene therapy in early-stage development. This positive clinical update for a key pipeline asset significantly de-risks the program and validates the company's therapeutic approach.
At the time of this announcement, TNYA was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.4M. The 52-week trading range was $0.44 to $2.35. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.